-+ 0.00%
-+ 0.00%
-+ 0.00%

UPDATE: FORTRESS BIOTECH’S SUBSIDIARY CYPRIUM THERAPEUTICS ENTERS INTO AGREEMENT TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR $205 MILLION

Reuters·02/23/2026 14:24:14

Please log in to view news